Recursion Pharmaceuticals (MEX:RXRX) General and Admin. Expense: MXN2,872 Mil (TTM As of Mar. 2026)


MEX:RXRX Recursion Pharmaceuticals Inc MEX:RXRX
57 GF Score
Price MXN62.20
GF Value MXN73.63
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals General and Admin. Expense?

Recursion Pharmaceuticals MEX:RXRX -10.37% 57 General and Admin. Expense is MXN2,872 Mil as of Mar. 2026. GuruFocus rates MEX:RXRX with a GF Score™ of 57/100 and a GF Value™ of MXN73.63 (Modestly Undervalued). The stock has 4 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Recursion Pharmaceuticals's General and Admin. Expense for the three months ended in Mar. 2026 was MXN624 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN2,872 Mil.

Recursion Pharmaceuticals General and Admin. Expense Related Terms

Recursion Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals General and Admin. Expense Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 1,183.29 1,590.85 1,881.12 3,716.15 3,179.61

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,118.04 878.44 763.63 606.02 623.77
MEX:RXRX
57GF Score
Recursion Pharmaceuticals Inc MEX:RXRX
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,872 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of MXN2,872 Mil mean?
Recursion Pharmaceuticals (MEX:RXRX) has a General and Admin. Expense of MXN2,872 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' General and Admin. Expense too high?
Recursion Pharmaceuticals' current General and Admin. Expense is MXN2,872 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' General and Admin. Expense compare to ABSI and GLUE?
Recursion Pharmaceuticals' General and Admin. Expense of MXN2,872 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current General and Admin. Expense is MXN2,872 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current General and Admin. Expense is MXN2,872 Mil. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current General and Admin. Expense is MXN2,872 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:RXRX:

  • General and Admin. Expense: MXN2,872 Mil
  • GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:USA
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score

Get the complete analysis for MEX:RXRX

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.20
Price
MXN73.63
GF Value